Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

David Wallace

Deputy Editor

Having previously worked in the European chemicals industry, Dave has now spent almost a decade with Generics bulletin. Bringing his background and education in law to bear on industry litigation - as well as national legislative and regulatory affairs - he also keeps a close eye on corporate strategy, personnel moves, and product pipelines. A regular delegate to industry events and conferences, he has a particular interest in local market developments, maintaining close links with national industry representatives. He also organizes and judges the annual Global Generics & Biosimilars Awards. A French speaker, Dave enjoys music - with a love of the piano - and visual arts.
Set Alert for Articles By David Wallace

Latest From David Wallace

Appeals Court Holds US Humira Patents Invalid

The US Court of Appeals for the Federal Circuit has upheld a series of inter partes review decisions from 2017 in which three Humira patents were found invalid by the Patent Trial and Appeal Board within the US Patent and Trademark Office.

Intellectual Property Biosimilars

USMCA Passes Muster In US Senate

The US Senate’s vote to approve legislation underpinning the US-Mexico-Canada trade agreement has been welcomed by the country’s off-patent industry.

Legislation Regulation

Industry Needs To Engage On Antimicrobials

Recruiting generics firms to the AMR Industry Alliance is a key area of focus for the group as part of its efforts to cover a greater proportion of the global supply of antimicrobials, according to the Alliance’s latest report.

Strategy Regulation

Samsung Bioepis Can Begin Eculizumab Trial In China

Samsung Bioepis and partner AffaMed Therapeutics have received an approval from the Chinese authorities to conduct a Phase III study for their eculizumab biosimilar rival to Soliris at Chinese sites. Meanwhile, Samsung Bioepis has also just completed a global Phase III trial for its ranibizumab version of Lucentis.

Biosimilars Strategy

UK Imipramine Prices Double In December

December brought price rises for the UK generics market that included imipramine prices as much as doubling and a leap of more than two-thirds in the average price of frovatriptan tablets.

Market Intelligence United Kingdom

Coherus Acquires Bevacizumab Rights From Innovent

Coherus BioSciences has struck a deal with China’s Innovent Biologics that gives it US and Canadian rights to a bevacizumab biosimilar version of Avastin as well as an option to market Innovent’s rituximab rival to Rituxan in the US and Canada.

Deals Biosimilars
See All
UsernamePublicRestriction

Register